Literature DB >> 23526163

Treatment response to preoperative anthracycline-based chemotherapy in locally advanced breast cancer: the relevance of proliferation and apoptosis rates.

Ksenija Kanjer1, Svetislav Tatić, Zora Nešković-Konstantinović, Zaki Abu Rabi, Dragica Nikolić-Vukosavljević.   

Abstract

Objectives were to evaluate the relevance of proliferating fraction (Ki-67) along with apoptotic index (AI) which denoted growth index (Ki-67/AI ratio, GI) to predict pathological response to preoperative chemotherapy, and the pattern of their modifications following chemotherapy in women with locally advanced breast cancer. Archival material of diagnostic biopsies and surgical specimens from 106 patients were examined. Response rate to chemotherapy in this group was 95 %, eight (8 %) patients achieved a pathological complete remission (pCR) and five (5 %) had a progressive/stable disease (PD/SD). The expression of Ki-67 and AI were assessed using immunohistochemistry and in situ DNA nick labeling assay respectively. Higher baseline level of Ki-67 and GI were associated with an improved pathological response (p = 0.0001 and p = 0.008), but the degree of correlation with GI was no greater than that with Ki-67 alone. Ki-67 below 1 % highly indicated a lack of tumor response. High AI which characterized the opposite chemo-sensitive tumors, pCR vs. PD/SD (p = 0.72) implied that treatment response was not influenced by the "presence" or "absence" of apoptosis. A significant decrease in Ki-67 (p < 0.001), AI (p = 0.035) and GI (p = 0.008) was found following chemotherapy, but percentage change in biomarker values revealed an increase in a number of cases. Higher initial Ki-67 and AI was associated with profound reduction of GI and raising value of GI after treatment, respectively. Such a variance of a given parameter elicited by chemotherapy may have various impact on disease outcome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23526163     DOI: 10.1007/s12253-013-9621-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  62 in total

1.  Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers.

Authors:  P Collecchi; E Baldini; P Giannessi; A G Naccarato; A Passoni; G Gardin; M Roncella; G Evangelista; G Bevilacqua; P F Conte
Journal:  Eur J Cancer       Date:  1998-10       Impact factor: 9.162

2.  Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy.

Authors:  P A Ellis; I E Smith; S Detre; S A Burton; J Salter; R A'Hern; G Walsh; S R Johnston; M Dowsett
Journal:  Breast Cancer Res Treat       Date:  1998-03       Impact factor: 4.872

Review 3.  Study of suboptimum treatment response: lessons from breast cancer.

Authors:  Per Eystein Lønning
Journal:  Lancet Oncol       Date:  2003-03       Impact factor: 41.316

4.  Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute.

Authors:  G Bonadonna; P Valagussa; C Brambilla; L Ferrari; A Moliterni; M Terenziani; M Zambetti
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

5.  Changes of biological features in breast cancer cells determined by primary chemotherapy.

Authors:  A Frassoldati; F Adami; C Banzi; M Criscuolo; L Piccinini; V Silingardi
Journal:  Breast Cancer Res Treat       Date:  1997-07       Impact factor: 4.872

Review 6.  Hallmarks of senescence in carcinogenesis and cancer therapy.

Authors:  Jerry W Shay; Igor B Roninson
Journal:  Oncogene       Date:  2004-04-12       Impact factor: 9.867

7.  Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy.

Authors:  Y Remvikos; P Beuzeboc; A Zajdela; N Voillemot; H Magdelénat; P Pouillart
Journal:  J Natl Cancer Inst       Date:  1989-09-20       Impact factor: 13.506

8.  Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.

Authors:  J Lee; Y H Im; S H Lee; E Y Cho; Y L Choi; Y H Ko; J H Kim; S J Nam; H J Kim; J S Ahn; Y S Park; H Y Lim; B K Han; J H Yang
Journal:  Cancer Chemother Pharmacol       Date:  2007-05-17       Impact factor: 3.333

9.  Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle.

Authors:  Maria Alicia H Navarrete; Carolina M Maier; Roberto Falzoni; Luiz Gerk de Azevedo Quadros; Geraldo R Lima; Edmund C Baracat; Afonso C P Nazário
Journal:  Breast Cancer Res       Date:  2005-02-16       Impact factor: 6.466

10.  Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.

Authors:  Gunter von Minckwitz; Hans-Peter Sinn; Günter Raab; Sibylle Loibl; Jens-Uwe Blohmer; Holger Eidtmann; Jörn Hilfrich; Elisabeth Merkle; Christian Jackisch; Serban D Costa; Angelika Caputo; Manfred Kaufmann
Journal:  Breast Cancer Res       Date:  2008-04-01       Impact factor: 6.466

View more
  5 in total

1.  The search for optimal cutoff points for apoptosis and proliferation rate in prognostification of early stage breast cancer patients treated with anthracyclines in adjuvant settings.

Authors:  Beata Biesaga; Joanna Niemiec; Joanna Wysocka; Dorota Słonina; Marek Ziobro
Journal:  Tumour Biol       Date:  2015-12-19

2.  Fractal and Gray Level Cooccurrence Matrix Computational Analysis of Primary Osteosarcoma Magnetic Resonance Images Predicts the Chemotherapy Response.

Authors:  Goran J Djuričić; Marko Radulovic; Jelena P Sopta; Marina Nikitović; Nebojša T Milošević
Journal:  Front Oncol       Date:  2017-10-19       Impact factor: 6.244

Review 3.  Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.

Authors:  Weilin Xu; Xiu Chen; Fei Deng; Jian Zhang; Wei Zhang; Jinhai Tang
Journal:  Onco Targets Ther       Date:  2020-06-22       Impact factor: 4.147

4.  A Novel Resveratrol-Arsenic Trioxide Combination Treatment Synergistically Induces Apoptosis of Adriamycin-Selected Drug-Resistant Leukemia K562 Cells.

Authors:  Jing Chen; Baoying Tian; Cunmin Zhou; Jingjing Sun; Li Lin; Shucheng Jin; Quanrui Liu; Siyu Fu; Lian Liu; Hang Liu; Zhewen Zhang; Caili Li; Hulai Wei
Journal:  J Cancer       Date:  2019-08-29       Impact factor: 4.207

5.  Glioblastoma multiforme versus pleomorphic xanthoastrocytoma with anaplastic features in the pathological diagnosis: a case report.

Authors:  Shoko M Yamada; Hideki Murakami; Yusuke Tomita; Makoto Nakane; Soichiro Shibui; Mikiko Takahashi; Masashi Kawamoto
Journal:  Diagn Pathol       Date:  2016-07-22       Impact factor: 2.644

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.